Medinol’s EluNir-Perl Coronary DES Approved by FDA

October 24, 2023—Medinol announced United States FDA approval for the EluNir-Perl drug-eluting stent (DES) for the treatment of coronary artery disease. EluNir-Perl builds upon the performance and clinical data of the EluNir DES system, which received FDA approval in 2017 for the treatment of patients with narrowing or blockages of their coronary arteries.

The company stated that EluNir-Perl features four radiopaque markers, two at each end of the stent, and a hybrid polymer-metal radiopaque catheter tip. These features allow outstanding visualization during percutaneous coronary intervention procedures whether navigating through complex anatomies or precise placement of the stent.

EluNir-Perl is exclusively available in the United States through CoSo Health, a healthcare supply and logistics company. Earlier this year, CoSo Health announced a distribution agreement with Medinol for its new-generation, thin-strut EluNir DES. CoSo Health uses a cloud-based logistics platform and customized direct-to–end user delivery model to distribute and sell devices. CoSo Health advised that it will work with U.S. Endovascular, which sells peripheral and coronary devices nationwide, and others to reach the United States market.